Early-onset retinal degenerative diseases, including those termed Leber congenital amaurosis, are a severe form of blindness without treatment. Mutations in the retinal pigment epithelium (RPE) gene encoding RPE65 are one of the few known molecular causes of these blinding diseases. The objective of this application is to investigate a potential oral therapy in animal models of RPE65-associated human retinal degeneration and determine the candidacy of patients with the molecularly comparable retinal disease. There is the advantage that both a genetically engineered murine """"""""small animal"""""""" model and a naturally occurring canine """"""""large animal"""""""" model are available. In preliminary studies, retinoid flow and retinal physiology in Rpe65-deficient mice were analyzed and there was no rod photo pigment and severely impaired rod physiology. There is a distinct disease phenotype with photoreceptor function severely abnormal at a time when morphology is nearly normal. Slow degeneration of photoreceptors and RPE causes a convergence of structural and functional damage at later disease stages. Using an orally-administered cis-retinoid, an attempt was made to bypass the biochemical blockade in the visual (retinoid) cycle caused by the genetic abnormality. Within 48 hours, there was formation of rod photopigment and dramatic improvement in rod physiology.
The specific aims of the current multi-disciplinary application lead directly from these encouraging results: (1) determine in Rpe65-deficient mice the short- and long-term consequences of oral cis-retinoids; (2) study the RPE65-mutant canine model for disease mechanism and response to oral cis-retinoids; and (3) define the disease expression in humans with early-onset retinal degenerations due to RPE65 mutations, specifically inquiring whether, like the models, there is a detectable phase when photoreceptor function is nearly absent but retinal structure remains, and thereby an opportunity for effective intervention independent of strategy. This application provides a route map that hopefully will be well-traveled in the future as we seek to restore vision in currently incurable genetic retinal degenerations from identification of molecular cause in human blindness, to experimentation and trials of mechanism-based intervention in small and large animal models, and then a circling back to the afflicted humans to clarify relevance to them and their candidacy for specific treatments, with the long-term goal of safe and efficacious clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
5R01EY013385-02
Application #
6518714
Study Section
Visual Sciences C Study Section (VISC)
Program Officer
Dudley, Peter A
Project Start
2001-04-01
Project End
2006-02-28
Budget Start
2002-03-01
Budget End
2003-02-28
Support Year
2
Fiscal Year
2002
Total Cost
$337,750
Indirect Cost
Name
University of Pennsylvania
Department
Ophthalmology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Cideciyan, Artur V; Aleman, Tomas S; Boye, Sanford L et al. (2008) Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A 105:15112-7
Jacobson, Samuel G; Boye, Sanford L; Aleman, Tomas S et al. (2006) Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. Hum Gene Ther 17:845-58
Jacobson, Samuel G; Acland, Gregory M; Aguirre, Gustavo D et al. (2006) Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. Mol Ther 13:1074-84
Williams, Melissa L; Coleman, Jason E; Haire, Shannon E et al. (2006) Lentiviral expression of retinal guanylate cyclase-1 (RetGC1) restores vision in an avian model of childhood blindness. PLoS Med 3:e201
Lebherz, Corinna; Maguire, Albert M; Auricchio, Alberto et al. (2005) Nonhuman primate models for diabetic ocular neovascularization using AAV2-mediated overexpression of vascular endothelial growth factor. Diabetes 54:1141-9
Maeda, Akiko; Maeda, Tadao; Imanishi, Yoshikazu et al. (2005) Role of photoreceptor-specific retinol dehydrogenase in the retinoid cycle in vivo. J Biol Chem 280:18822-32
Jacobson, Samuel G; Aleman, Tomas S; Cideciyan, Artur V et al. (2005) Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy success. Proc Natl Acad Sci U S A 102:6177-82
Schwartz, Sharon B; Aleman, Tomas S; Cideciyan, Artur V et al. (2005) Disease expression in Usher syndrome caused by VLGR1 gene mutation (USH2C) and comparison with USH2A phenotype. Invest Ophthalmol Vis Sci 46:734-43
Maeda, Akiko; Crabb, John W; Palczewski, Krzysztof (2005) Microsomal glutathione S-transferase 1 in the retinal pigment epithelium: protection against oxidative stress and a potential role in aging. Biochemistry 44:480-9
Golczak, Marcin; Kuksa, Vladimir; Maeda, Tadao et al. (2005) Positively charged retinoids are potent and selective inhibitors of the trans-cis isomerization in the retinoid (visual) cycle. Proc Natl Acad Sci U S A 102:8162-7

Showing the most recent 10 out of 34 publications